Agamree is a new-type drug for the treatment of Duchenne Muscular Dystrophy (DMD). Its price, purchasing channels and therapeutic effects are the key concerns of patients and their families. Agamree has been launched in Germany, the United States and the United Kingdom, but it has not yet been launched in China and is not included in China's medical insurance. The price of the original Agamree developed by Santhera Pharmaceuticals of Switzerland is approximately $5,435 per box.

How Much Does a Box of Agamree Cost?

Agamree is an innovative drug, and its pricing reflects the R&D costs and clinical value. Patients can consult their attending physicians to learn about the specific cost composition and possible payment assistance programs.

Official Pricing Information

According to the price announced by Santhera Pharmaceuticals, a Swiss pharmaceutical company, the selling price of one box of Agamree is approximately $5,435. This price applies to the 100mL oral suspension with a concentration of 40mg/mL. The above price is for reference only, and the specific price shall be subject to the actual situation.

Factors Affecting the Price

Drug prices may fluctuate due to regions, tax policies and mark-ups by medical institutions. Patient assistance programs in some countries or regions may offer price discounts.

Estimated Total Cost for the Entire Treatment Course

Calculated according to the standard treatment plan, a complete treatment course may require multiple boxes of the drug, and the total cost may reach tens of thousands of US dollars. The specific cost depends on the patient's weight, administration plan and treatment cycle.

How to Purchase Agamree?

At present, Agamree has not been launched in China, so patients need to obtain it through specific channels. Patients should avoid obtaining the drug through irregular channels to prevent adverse effects on the therapeutic effect and safety.

Overseas Medical Institutions

Medical institutions in countries where Agamree has been launched, such as Germany, the United States and the United Kingdom, can provide Agamree. Patients can obtain the drug through cross-border medical services, but they need to pay attention to the drug transportation and storage conditions.

Seeking Professional Medical Consultation

Before purchasing Agamree, it is recommended that patients seek professional medical consultation. Doctors or medical experts can provide personalized drug purchase suggestions and precautions based on the specific conditions of patients to ensure that patients can use this drug safely and effectively.

How Effective is Agamree in Treatment?

Agamree has shown unique clinical value in the treatment of DMD.

Clinical Efficacy Data

Key clinical trials have shown that Agamree can significantly improve the muscle function and quality of life of DMD patients. Compared with traditional glucocorticoids, it has fewer adverse reactions related to bones and growth.

Wide Applicable Population

Agamree is suitable for DMD patients aged 4 and above, regardless of their underlying mutations and walking status. This provides treatment opportunities for patients at different stages of the disease.

Safety Characteristics

Although adverse reactions such as Cushing-like changes may occur, the overall safety is better than that of traditional glucocorticoids. Through standardized dose adjustment and monitoring, most patients can tolerate the treatment.

Agamree has brought a new treatment option for DMD patients. Under the guidance of professional physicians, patients should weigh the therapeutic effects and risks and formulate individualized treatment plans.